<DOC>
	<DOCNO>NCT01030536</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose ( MTD ) optimal biologic dose ( OBD ) safety profile CAT-8015 subject relapse refractory advance B-cell NHL ( DLBCL , FL , MCL ) CLL .</brief_summary>
	<brief_title>Safety Study CAT-8015 Treat Advanced B-cell Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia ( NHL CLL )</brief_title>
	<detailed_description>To determine maximum tolerate dose ( MTD ) optimal biologic dose ( OBD ) CAT-8015 subject relapse refractory advance B-cell NHL ( DLBCL , FL , MCL ) CLL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>Inclusion Criteria Subjects must least 18 year age old Written inform consent HIPAA authorization Subjects must histologicallyconfirmed Bcell CLL , include SLL , DLBCL , MCL , FL . Bcell NHL ( DLBCL , FL , MCL ) : Have previous confirmation Bcell NHL Subjects DLBCL MCL , must relapse refractory disease least one prior regimen contain rituximab , either alone combination , ineligible available standard line therapy know lifeprolonging lifesaving . Subjects FL , must relapse refractory disease least two prior regimen , one include rituximab , either alone combination , ineligible available standard line therapy know lifeprolonging lifesaving . Have measurable disease ( least one lesion ≥ 20 mm one dimension ≥ 15 mm two dimension measure conventional high resolution [ spiral ] compute tomography ( CT ) Not candidate hematopoietic stem cell ( HSC ) bone marrow ( BM ) transplant Bcell CLL : Have previous confirmation Bcell CLL characteristic immunophenotype flow cytometry Have relapse refractory disease least 2 prior line treatment , least 1 must contain rituximab ineligible available standard line therapy know lifeprolonging lifesaving Not candidate HSC BM transplant Have symptomatic disease require treatment Karnofsky Performance Status ≥ 70 Life expectancy ≥ 12 week Toxicities previous cancer therapy must recover Grade &lt; 2 . Adequate hematological function define : Hemoglobin ≥ 9 g/dL Absolute neutrophil count ≥ 1500/mm3 Platelet count ≥ 75,000/mm3 ( ( except CLL subject evidence bone marrow disease , must platelet count ≥ 50,000/mm3 ) Adequate organ function define follow : AST ALT ≤ 2 × institutional ULN , except case liver involvement ≤ 5 × ULN Bilirubin ≤ 1.5 × ULN , except case subject document Gilbert 's disease ≤ 2.5 × ULN Creatinine clearance ≥ 50 mL/min determine CockcroftGault equation 24hour urine collection determination creatinine clearance PTINR/ PTT ≤ 1.5 × ULN , patient anticoagulation therapy , status within therapeutic range Women nonchildbearing potential use effective contraception Male subject partner childbearing potential must surgically sterile use contraceptive method For expansion phase , subject DLBCL , FL , MCL , disease must evaluable International Working Group criterion ( Cheson et al , 2007 ) . Exclusion Criteria Any follow excludes subject participation study : Any available standard line therapy know lifeprolonging lifesaving Any concurrent chemotherapy , radiotherapy , immunotherapy , biologic , hormonal therapy treatment cancer For CLL patient , rapidly progressive disease estimation investigator sponsor would compromise ability complete study therapy History allergy reaction component CAT8015 formulation Receipt chemotherapy small molecule target therapy regimen within 6 week Receipt biological immunologicalbased therapy leukemia lymphoma within 6 week Prior radiation therapy exclude , provide volume bone marrow treat less 25 % . Any history prior pseudomonasexotoxin ( PE ) immunotoxin administration include CAT8015 , CAT3888 , LMB2 ( antiCD25 immunotoxin ) History invasive malignancy within 5 year , exception Evidence significant active infection require antimicrobial , antifungal , antiparasitic antiviral therapy supportive care give Autologous stem cell transplantation within 6 month prior study entry Allogenic stem cell transplantation organ transplant HIVpositive AIDS Hepatitis B hepatitis C infection define seropositive hepatitis B ( HBsAg ) hepatitis C elevate liver transaminase Use immunosuppressive medication steroid within 7 day Use systemic steroid within 7 day first dose CAT8015 ( inhaled topical corticosteroid permit ) . Subjects may take replacement dos steroid ( define ≤ 30 mg/day hydrocortisone equivalent ) stable dose least 2 week prior first dose CAT8015 . Documented current central nervous system involvement leukemia lymphoma Pregnancy lactation Other severe , concurrent disease Concurrent enrollment another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>NHL</keyword>
	<keyword>CLL</keyword>
</DOC>